©2022 Stanford Medicine
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Trial ID: NCT00136084
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
- Diagnosis of acute myeloid leukemia by immunophenotyping, morphology, and cytochemical
staining; myelodysplasia; or biphenotypic leukemia.
- Age less than or equal to 21 years at time of study entry.
- No prior therapy for this malignancy (patients with secondary AML following treatment
of primary malignancy are eligible) except for one dose of intrathecal therapy.
- Negative pregnancy test
- Patient does not have Down syndrome, acute promyelocytic leukemia (APL), or juvenile
myelomonocytic leukemia (JMML)
- Positive pregnancy test
- Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia
drug: Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
drug: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
LPCH New Patient Coordinator